Entrada Therapeutics (TRDA) Free Cash Flow (2020 - 2026)

Entrada Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$41.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 5.15% year-over-year to -$41.7 million; the TTM figure through Mar 2026 stood at -$131.6 million (down 137.49% YoY), while the FY2025 annual figure was -$129.6 million, down 207.6% from the prior year.
• Free Cash Flow was -$41.7 million for Q1 2026 at Entrada Therapeutics, down from -$33.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $201.7 million in Q1 2023 to a low of -$41.7 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$9.9 million across 5 years, with a median of -$26.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow jumped 1043.46% in 2023, then sank 718.59% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$25.2 million in 2022, then surged by 84.44% to -$3.9 million in 2023, then sank by 718.59% to -$32.1 million in 2024, then retreated by 3.55% to -$33.2 million in 2025, then retreated by 25.42% to -$41.7 million in 2026.
• The last three Free Cash Flow figures came in at -$41.7 million (Q1 2026), -$33.2 million (Q4 2025), and -$28.3 million (Q3 2025), per Business Quant data.